Patents by Inventor Fabio Neggiani
Fabio Neggiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230082870Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: October 25, 2022Publication date: March 16, 2023Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Patrizia Chetoni, Silvia Tampucci
-
Patent number: 11512104Abstract: The present invention relates to a new process for the preparation of the crystalline polymorph of sodium neridronate in form hemihydrate F, comprising the following steps: a) reacting the 6-aminohexanoic acid with a mixture of phosphorous acid and methanesulfonic acid at a temperature in the range from 60 to 80° C., under stirring, until a clear solution is obtained; b) adding phosphorus trichloride to said solution of step (a) under stirring at a temperature in the range of 60 to 80° C.; c) diluting with water the reaction mixture obtained from the previous step (b) and heating said water diluted mixture at a temperature in the range from 80 to 120° C.; d) cooling the heated mixture obtained in step (c) up to room temperature, diluting it with water, then slowly adding an aqueous sodium hydroxide solution up to a pH in the range from 4.2 to 4.6, to obtain a neutralized solution; e) bringing the neutralized solution of step (d) up to a temperature of about 70° C.Type: GrantFiled: June 5, 2020Date of Patent: November 29, 2022Assignee: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Stefano Luca Giaffreda, Serena Fabbroni, Michel Chiarucci, Barbara Politi
-
Publication number: 20220267359Abstract: The present invention relates to a new process for the preparation of the crystalline polymorph of sodium neridronate in form hemihydrate F, comprising the following steps: a) reacting the 6-aminohexanoic acid with a mixture of phosphorous acid and methanesulfonic acid at a temperature in the range from 60 to 80° C., under stirring, until a clear solution is obtained; b) adding rl phosphorus trichloride to said solution of step (a) under stirring at a temperature in the range of 60 to 80° C.; c) diluting with water the reaction mixture obtained from the previous step (b) and heating said water diluted mixture at a temperature in the range from 80 to 120° C.; d) cooling the heated mixture obtained in step (c) up to room temperature, diluting it with water, then slowly adding an aqueous sodium hydroxide solution up to a pH in the range from 4.2 to 4.6, to obtain a neutralized solution; e) bringing the neutralized solution of step (d) up to a temperature of about 70° C.Type: ApplicationFiled: June 5, 2020Publication date: August 25, 2022Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Stefano Luca Giaffreda, Serena Fabbroni, Michel Chiarucci, Barbara Politi
-
Patent number: 11123354Abstract: The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.Type: GrantFiled: December 6, 2017Date of Patent: September 21, 2021Assignee: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Silvia Trasciatti
-
Patent number: 11058138Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: GrantFiled: September 6, 2018Date of Patent: July 13, 2021Assignee: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Samuele Zanatta
-
Publication number: 20200375238Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: September 6, 2018Publication date: December 3, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Samuele Zanatta
-
Publication number: 20200375897Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.Type: ApplicationFiled: September 6, 2018Publication date: December 3, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Patrizia Chetoni, Silvia Tampucci
-
Patent number: 10815257Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).Type: GrantFiled: April 10, 2019Date of Patent: October 27, 2020Assignee: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
-
Publication number: 20200061088Abstract: The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.Type: ApplicationFiled: December 6, 2017Publication date: February 27, 2020Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Silvia Trasciatti
-
Publication number: 20190308999Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).Type: ApplicationFiled: April 10, 2019Publication date: October 10, 2019Applicant: ABIOGEN PHARMA S.P.A.Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
-
Publication number: 20110039902Abstract: A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydroben-zo[d]isoxazol-4-one with oxalic acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having a dielectric constant ? within the range from 4 to 25. The process of the invention enables a co-crystal comprising 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and oxalic acid to be obtained.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Applicant: ABIOGEN PHARMA S.P.A.Inventors: Fabio Neggiani, Elio Napolitano, Simone Basagni, Barbara Politi
-
Publication number: 20110039901Abstract: A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and fumaric acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having a dielectric constant ? in the range from 4 to 25. The process of the invention enables to obtain a co-crystal comprising 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and fumaric acid.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Inventors: Simone Basagni, Fabio Neggiani, Barbara Politi, Elio Napolitano
-
Publication number: 20100069451Abstract: The present invention relates to oxalate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns oxalate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one.Type: ApplicationFiled: October 31, 2007Publication date: March 18, 2010Applicant: ABIOGEN PHARMA S.P.AInventors: Fabio Neggiani, Laura Dini
-
Publication number: 20100069450Abstract: The present invention relates to fumarate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns fumarate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one.Type: ApplicationFiled: October 31, 2007Publication date: March 18, 2010Applicant: ABIOGEN PHARMA S.P.AInventors: Fabio Neggiani, Laura Dini